Chordate has chosen RQM+ to prepare a marketing authorization application in the US

Chordate Medical Holding AB (publ) ("Chordate") will partner with RQM + in the project to obtain a marketing authorization for the K.O.S treatment for chronic migraine from the US Food and Drug Administration, FDA. RQM + is one of the world's largest regulatory and quality consulting firm focused on medical devices and diagnostics.

"This project is an important step in our strategy to build company value, and it is necessary to choose a competent partner with extensive experience of this type of project, which we get with RQM +", says Anders Weilandt, CEO of Chordate.

As Chordate announced in October 2021, the company has made a strategic decision to initiate a pre-study study to apply for marketing authorization for the K.O.S treatment for chronic migraine with the US Food and Drug Administration, FDA. The pre-study will begin immediately through the collaboration with RQM+ and can be expected to be completed within the first quarter of 2022, when a decision on the choice of strategy can be made.

This disclosure was submitted for publication, through the contact person below, on December 13th, 2021, at 15:15 am CET.

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277

The following documents can be retrieved from beQuoted

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more at

More press releases

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact